Clinical trials: Demyelinating Disorder
Multiple Sclerosis
A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis
A Phase I Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis to demonstrate safety \& efficacy
- Trial name
- NCT02200718
- Testing
- NeuroVax, IFA Incomplete Freund's Adjuvant
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Immune Response BioPharma, Inc.
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine [23-PPV] either unboosted or boosted…
- Trial name
- NCT02545868
- Testing
- 23-PPV, 13-PCV Booster, Influenza Vaccine
- Where
- 22 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
A First-in-Patient Clinical Trial of KINE-101 in Patients With Corticosteroid-Refractory CIDP
This is a multicenter, open-label, single-dose, dose-escalation study evaluating the safety and tolerability of intravenous (IV) KINE-101 in patients with corticosteroid-refractory chronic inflammatory demyelinating…
- Trial name
- NCT07343310
- Testing
- KINE-101
- Where
- 2 sites in South Korea
- Volunteers
- 9 people
- Sponsor
- Kine Sciences Co., Ltd.
Secondary Progressive Multiple Sclerosis
Study Evaluating Mitoxantrone in Multiple Sclerosis
The purpose of this study is to show the dose-response relationship of three doses of mitoxantrone with regard to efficacy in patients with secondary progressive multiple sclerosis and to show the safety and tolerability of…
- Trial name
- NCT00146159
- Testing
- Mitoxantrone
- Where
- 7 sites in Germany
- Volunteers
- 336 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Multiple Sclerosis
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
This 12-year study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic (PD) effects of ocrelizumab in children and adolescents ages ≥ 10 to ≤ 18 years with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT04075266
- Testing
- Ocrelizumab
- Where
- 12 sites in United States, Italy and 1 more
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Multiple Sclerosis, Relapsing-Remitting
An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters
The present study aims to assess the adherence to therapy with interferon beta-1a (Rebif®) and at investigating potential factors that are involved in its outcome, in a representative sample of patients with relapsing remitting…
- Trial name
- NCT01112345
- Where
- Greece
- Volunteers
- 133 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Neuromyelitis Optica Spectrum Disorders
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
To evaluate the efficacy and safety of B001 injection in aquaporin-4 antibody positive patients with neuromyelitis optica spectrum disorder.
- Trial name
- NCT06413654
- Testing
- B001
- Where
- 51 sites in China
- Volunteers
- 132 people
- Sponsor
- Shanghai Jiaolian Drug Research and Development Co., Ltd
Progressive Multifocal Leukoencephalopathy
Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy
The purpose of this study is to explore host genetic mutations which may render individual subjects more susceptible (or resistant) to developing Progressive Multifocal Leukoencephalopathy (PML).
- Trial name
- NCT01211639
- Where
- 11 sites in United States, Germany
- Volunteers
- 24 people
- Sponsor
- Biogen
Multiple Sclerosis
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in patients with multiple sclerosis.
- Trial name
- NCT01764737
- Testing
- VX15/2503
- Where
- 10 sites in United States
- Volunteers
- 50 people
- Sponsor
- Vaccinex Inc.
Relapsing-Remitting Multiple Sclerosis
Safety and Tolerability of Glatiramer Acetate
This is an open-label, randomized, multi-center, parallel-arm study to assess the safety and tolerability of a daily dose of Glatiramer Acetate (GA) 40 mg/mL three times a week (TIW) administered subcutaneously (SC) as compared…
- Trial name
- GLACIER (NCT01874145)
- Testing
- GA 20 mg/mL, GA 40 mg/mL
- Where
- 35 sites in United States
- Volunteers
- 209 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Multiple Sclerosis, Relapsing-Remitting
Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study Two
The purpose of this study was to establish the efficacy and safety of two different doses of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous interferon…
- Trial name
- CARE-MS II (NCT00548405)
- Testing
- Alemtuzumab 12 mg, Alemtuzumab 24 mg, Interferon beta-1a
- Where
- 191 sites in United States, Argentina and 21 more
- Volunteers
- 840 people
- Sponsor
- Genzyme, a Sanofi Company
Multiple Sclerosis
A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy
This study has patients responding to two sets of surveys that will tell their doctor or nurse about their readiness to begin self-injection.
- Trial name
- NCT00238654
- Volunteers
- 257 people
- Sponsor
- Teva Neuroscience, Inc.
Multiple Sclerosis, Relapsing-Remitting
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
The purpose of this prospective, multicenter, open-label, efficacy, and safety study is to assess the efficacy and safety of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who have had a suboptimal…
- Trial name
- NCT02861014
- Testing
- Ocrelizumab
- Where
- 163 sites in Australia, Belgium and 15 more
- Volunteers
- 681 people
- Sponsor
- Hoffmann-La Roche
Relapsing-Remitting Multiple Sclerosis
Tysabri Observational Program
The primary objective of this study is to assess the long-term safety and impact on disease activity and progression of Tysabri in participants with relapsing remitting multiple sclerosis (RRMS) in a clinical practice setting.
- Trial name
- TOP (NCT00493298)
- Testing
- Tysabri
- Where
- 419 sites in Argentina, Australia and 16 more
- Volunteers
- 6,620 people
- Sponsor
- Biogen
Multiple Sclerosis
A Study of ALKS 8700 in Adults With Relapsing Remitting Multiple Sclerosis (MS) EVOLVE-MS-1
The primary objective of this study is to evaluate the long-term safety and tolerability of ALKS 8700 for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- NCT02634307
- Testing
- ALKS 8700
- Where
- 115 sites in United States, Belgium and 8 more
- Volunteers
- 1,057 people
- Sponsor
- Biogen
Multiple Sclerosis (Relapsing Remitting)
Safety and Efficacy of Fingolimod in MS Patients in China
To evaluate the safety and efficacy of fingolimod 0.5mg vs. placebo in MS patients in China
- Trial name
- NCT01941004
- Testing
- fingolimod
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants
The purpose of this retrospective observational cohort study is to assess pregnancy and infant outcomes in three groups: the first is women with multiple sclerosis (MS) who were exposed to ozanimod during pregnancy; the second is…
- Trial name
- NCT06133049
- Testing
- Ozanimod, Select DMTs other than ozanimod, No DMTs
- Where
- United States
- Volunteers
- 2,961 people
- Sponsor
- Bristol-Myers Squibb
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
The purpose of the study is to assess long-term safety and tolerability of weekly doses of rozanolixizumab in subjects with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).
- Trial name
- NCT04051944
- Testing
- Rozanolixizumab
- Where
- 14 sites in United States, Belgium and 6 more
- Volunteers
- 21 people
- Sponsor
- UCB Biopharma SRL
Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 in adult participants with neurological autoimmune diseases (AIDs), including Progressive…
- Conditions
- Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Autoimmune Encephalitis
- Trial name
- CRSP-AID-502 (NCT07804004)
- Testing
- CTX112
- Volunteers
- 220 people
- Sponsor
- CRISPR Therapeutics
Neuromyelitis Optica Spectrum Disorder
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
The purpose of this study is to understand the effects of long-term treatment with inebilizumab on circulating levels of immunoglobulins, B-cell counts, and other safety measures, and to further monitor repletion of immunoglobins…
- Trial name
- N-MOmentum LT (NCT06180278)
- Testing
- Blood tests, Inebilizumab
- Where
- 11 sites in United States, China and 5 more
- Volunteers
- 32 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.